Press release
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from ~USD 310 Million in 2024 | DelveInsight
Pheochromocytomas and Paragangliomas Market Report
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM, which include, US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report presents a detailed analysis of pheochromocytomas market trends, therapeutic landscapes, and unmet needs, providing valuable strategic insights for stakeholders in this specialized neuroendocrine tumor market.
The pheochromocytomas and paragangliomas market is poised for significant expansion, with the market size across the 7MM estimated at approximately USD 310 million in 2024. This growth trajectory is primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options targeting specific molecular pathways. The US currently holds the largest pheochromocytoma market share, accounting for approximately USD 190 million in 2024, with promising growth expected in the coming decade due to favorable reimbursement policies and rapid adoption of innovative treatment modalities.
Download the Pheochromocytomas and Paragangliomas Market report to understand which factors are driving the PCPG therapeutic market @ Pheochromocytomas and Paragangliomas Market Trends [https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The pheochromocytomas and paragangliomas epidemiological landscape reveals approximately 5K incident cases across the 7MM in 2024, with projections indicating sustained growth throughout the forecast period. Genetic analysis has become increasingly important in pheochromocytomas and paragangliomas management, with nearly 75% of US cases showing germline or somatic mutations in 2024. Among the EU4 and UK markets, which collectively reported approximately 2K incident cases in 2024, Germany accounted for the highest disease burden, while Spain demonstrated the lowest incidence. Japan shows a noteworthy pattern with localized pheochromocytoma cases significantly outnumbering metastatic presentations.
Discover evolving trends in the Pheochromocytomas and Paragangliomas patient pool forecasts @ Pheochromocytomas and Paragangliomas Epidemiology Analysis [https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also analyses the current and emerging pheochromocytoma and paraganglioma treatment landscape. The current therapeutic landscape varies based on disease staging and functional status. For localized tumors, radical surgical resection remains the cornerstone of treatment, representing the only potentially curative intervention. The metastatic pheochromocytoma treatment paradigm has evolved toward a multidisciplinary approach encompassing debulking surgery, chemotherapy (particularly the cyclophosphamide, vincristine, and dacarbazine regimen), tyrosine kinase inhibitors, immunotherapies, and advanced radionuclide therapies. Radionuclide injection, a targeted treatment option, is also used for pheochromocytoma and paraganglioma treatment, especially in metastatic or inoperable cases.
Key marketed treatments include DEMSER (metyrosine) from Bausch Health (NYSE: BHC) and Ono Pharmaceutical (TYO: 4528). This oral tyrosine hydroxylase inhibitor remains an important option for preoperative preparation and chronic management of malignant pheochromocytoma. In July 2020, the FDA approved Amneal Pharmaceuticals' generic version of DEMSER oral capsules.
The treatment landscape has faced challenges, including the AZEDRA discontinuation in 2023, due to commercial non-viability. AZEDRA, manufactured by Lantheus Holdings (NASDAQ: LNTH), was approved by the FDA in 2018 based on Study IB12 B.
Despite the challenges [https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] associated with drug development for ultra-rare diseases, the pheochromocytomas and paragangliomas pipeline demonstrates significant innovation, with several promising candidates advancing through clinical development.
In January 2025, the FDA accepted for Priority Review a supplemental New Drug Application for Merck's WELIREG (belzutifan) for treating adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytomas and paragangliomas. Welireg MOA involves blocking HIF-2, which helps tumors grow in low-oxygen conditions. With a PDUFA date of May 26, 2025, WELIREG is positioned to potentially capture substantial market share upon approval.
Other notable emerging therapies include Chimerix's ONC201, a first-in-class small molecule imipridone that selectively binds to dopamine receptor D2 and mitochondrial protease ClpP. ONC201 demonstrated a 50% objective response rate in paraganglioma during Phase II studies. Novartis (SWX: NOVN) is advancing LUTATHERA, a radiopharmaceutical that targets somatostatin receptors.
Additionally, in November 2024, Perspective Therapeutics (NYSE: CATX) presented promising initial results from its Phase I/IIa clinical trial of VMT--NET at the 2024 NANETS Multidisciplinary NET Medical Symposium.
Discover recent advancements in the Pheochromocytomas and Paragangliomas treatment landscape @ Pheochromocytomas and Paragangliomas Recent Developments [https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The therapeutic landscape is increasingly focusing on targeted approaches based on tumor genetic profiles, with treatments tailored to specific molecular clusters. These include radionuclide therapies with SSTR2 agonists/antagonists, cold SSTR2 analogs, HIF-2 inhibitors, and novel DRD2 and ClpP agonists. This precision medicine approach represents a paradigm shift from traditional symptom management to molecularly targeted interventions that address the underlying pathophysiology of these rare neuroendocrine tumors.
Despite therapeutic advances, significant challenges remain in pheochromocytomas and paragangliomas management, including the heterogeneity of tumor behavior, limited treatment options for metastatic disease, and the need for improved biomarkers to guide therapy selection. The market is expected to witness continued growth driven by increased disease recognition, expanded genetic testing, and the introduction of innovative treatment modalities that address current unmet needs in this specialized oncology segment.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. PCPG MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET METHODOLOGY
7. PCPG BACKGROUND AND OVERVIEW
8. PCPG TREATMENT AND MANAGEMENT
9. PCPG EPIDEMIOLOGY AND PATIENT POPULATION
10. PCPG PATIENT JOURNEY
11. PCPG MARKETED DRUGS
12. PCPG DISCONTINUED PRODUCT
13. PCPG EMERGING DRUGS
14. PCPG: SEVEN MAJOR MARKET ANALYSIS
15. PCPG UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pheochromocytomas-and-paragangliomas-market-to-grow-significantly-by-2034-from-usd-310-million-in-2024-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from ~USD 310 Million in 2024 | DelveInsight here
News-ID: 3996041 • Views: …
More Releases from ABNewswire
Dollar Land Store Makes Land Ownership the Ultimate Holiday Gift with $1 Down Op …
Dollar Land Store is helping families across America achieve the dream of land ownership this holiday season with affordable seller-financed properties. With over a decade of experience, the company offers deeded land in multiple states with transparent pricing and personalized support throughout the entire purchasing process.
As the holiday season brings families together to reflect on their dreams and goals, Dollar Land Store is opening doors to land ownership for everyday…
The Evolution of Forex Trading Education And Structured Learning Platforms | Lea …
LearnForex.live outlines recent developments in structured online education and how curriculum-led learning platforms are addressing the growing demand for accessible forex market education.
Dubai, UAE - December 19, 2025 - As global interest in financial literacy continues to grow, structured education models are becoming an increasingly important component of learning about complex markets such as foreign exchange. Educational platforms and specialized websites now provide curriculum-based instruction that helps learners explore market…
Dynamic Home Activities and Dependable Digital Infrastructure
Modern homes feel more active than ever. People work, relax, learn, and connect from the same rooms each day. This shift pushes technology into the center of daily routines. Families rely on smart devices, fast internet, and stable connections to keep things running. Home activities now depend on digital systems that work without constant attention.
People want tools that save time and reduce stress. They also want connections that support video…
Modern Living Room: Simple Steps to a Fresh, Stylish Home
The living room is often called the heart of the home, a special spot where families gather, friends visit, and happy memories are made. In a modern living room, the goal is to mix style, comfort, and functionality to create a place that looks good and works well for your life. You don't need a huge renovation or a lot of money to make your space look completely new and…
More Releases for Pheochromocytomas
Pheochromocytomas and Paragangliomas Market Size is projected to grow at a CAGR …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of PCPG, historical and forecasted epidemiology as well as Pheochromocytomas and Paragangliomas therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Pheochromocytomas/Paragangliomas Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Pheochromocytomas/Paragangliomas Market Report
• In November…
Pheochromocytomas and Paragangliomas (PCPG) Market is projected to reach USD 1.2 …
The global Pheochromocytomas and Paragangliomas (PCPG) Market was valued at USD 650 million in 2024 and is projected to reach USD 1.24 billion by 2034, growing at a CAGR of 6.7% during the forecast period (2025-2034). Increasing detection of rare endocrine tumors, advancements in molecular diagnostics, expanding research on genetic mutations, and rising adoption of targeted therapies are key factors supporting market growth.
Download Full PDF Sample Copy of Market Report…
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from …
The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034"[https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment paradigms,…
Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From …
Pheochromocytomas and Paragangliomas (PPGL) Market Outlook 2024-2034: Rising Awareness and Targeted Therapies Drive Growth
Introduction
Pheochromocytomas and paragangliomas (collectively known as PPGL or PCPG) are rare neuroendocrine tumors that originate from chromaffin cells in the adrenal medulla or extra-adrenal paraganglia. While pheochromocytomas arise in the adrenal glands, paragangliomas occur in various parts of the body including the abdomen, chest, and head-and-neck region.
Although rare, these tumors can be life-threatening if untreated, often associated…
Pheochromocytomas and Paragangliomas Market
Introduction
Pheochromocytomas and Paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla (pheochromocytomas) or extra-adrenal ganglia (paragangliomas). These tumors often produce excess catecholamines, leading to hypertension, palpitations, headaches, and cardiovascular complications. While typically benign, a subset may become malignant, significantly complicating patient management.
Historically, PPGLs have been underdiagnosed due to their nonspecific symptoms, but advances in genetic testing, imaging, and biochemical assays have improved detection. With…
Pheochromocytomas and Paragangliomas Market Forecast - Unlocking Rare Tumor Insi …
Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors originating from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. While pheochromocytomas typically arise in the adrenal glands, paragangliomas can develop anywhere along the sympathetic and parasympathetic chains. Though generally benign, these tumors can secrete excess catecholamines, leading to severe cardiovascular complications such as hypertension, arrhythmias, and even stroke, if not diagnosed and managed promptly.
DelveInsight's comprehensive report, "Pheochromocytomas and Paragangliomas…
